ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP67-20 Commercial Pharmacy Benefit Exclusion for DurystaTM, Iluvien®, Retisert® and Yutiq®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 22, 2020
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 2351 - 2360 လၢ 3159 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-20 MDH Guidance to Support Hospital Patients with Disabilities and Pediatric Patients
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 22, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP59-20 MHCP Pharmacy Benefit Exclusion for DurystaTM and Fensolvi®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 08, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP60-20 Commercial Pharmacy Benefit Exclusion for Procysbi® Delayed-Release Granules
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 08, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP61-20 Signify Health Virtual Visits for Medicare Advantage and SecureBlue Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 08, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP58-20 Commercial Pharmacy Benefit Exclusion for Medical Drugs Anjeso™ , Fetroja™ and Potassium Phosphates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 08, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P52-20 Emergency Department Level of Service Coding Reimbursement Policy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P53-20 New Reimbursement Policy: Inpatient Non-Reimbursable Unbundling
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P46-20 Genetic/Molecular Lab Test Coding Reimbursement Policy
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2020
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P48-20 CMS Issued Prior Authorization Requirements for Certain Hospital Outpatient Department (OPD) Services – Effective July 1, 2020
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယူၤလံ 01, 2020